Author Archives: admin


Scientists Grew ‘Mini Brains’ From Stem Cells. Then, The Brains Sort-of Developed Eyes. – ScienceAlert

Mini brains grown in a lab from stem cells spontaneously developed rudimentary eye structures, scientists reported in a fascinating paper in 2021.

On tiny, human-derived brain organoids grown in dishes, two bilaterally symmetrical optic cups were seen to grow, mirroring the development of eye structures in human embryos.

This incredible result will help us to better understand the process of eye differentiation and development, as well as eye diseases.

"Our work highlights the remarkable ability of brain organoids to generate primitive sensory structures that are light sensitive and harbor cell types similar to those found in the body," said neuroscientist Jay Gopalakrishnan of University Hospital Dusseldorf in Germany.

"These organoids can help to study brain-eye interactions during embryo development, model congenital retinal disorders, and generate patient-specific retinal cell types for personalized drug testing and transplantation therapies."

Brain organoids are not true brains, as you might be thinking of them. They are small, three-dimensional structures grown from induced pluripotent stem cells - cells harvested from adult humans and reverse engineered into stem cells, that have the potential to grow into many different types of tissue.

In this case, these stem cells are coaxed to grow into blobs of brain tissue, without anything resembling thoughts, emotions, or consciousness.

Such 'mini brains' are used for research purposes where using actual living brains would be impossible, or at the very least, ethically tricky - testing drug responses, for example, or observing cell development under certain adverse conditions.

This time, Gopalakrishnan and his colleagues were seeking to observe eye development.

In previous research, other scientists had used embryonic stem cells to grow optic cups, the structures that develop into almost the entire globe of the eye during embryonic development. And other research had developed optic cup-like structures from induced pluripotent stem cells.

Rather than grow these structures directly, Gopalakrishnan's team wanted to see if they could be grown as an integrated part of brain organoids. This would add the benefit of seeing how the two types of tissue can grow together, rather than just growing optic structures in isolation.

"Eye development is a complex process, and understanding it could allow underpinning the molecular basis of early retinal diseases," the researchers wrote in their paper.

"Thus, it is crucial to study optic vesicles that are the primordium of the eye whose proximal end is attached to the forebrain, essential for proper eye formation."

Previous work in the development of organoids showed evidence of retinal cells, but these did not develop optic structures, so the team changed their protocols. They didn't attempt to force the development of purely neural cells at the early stages of neural differentiation, and added retinol acetate to the culture medium as an aid to eye development.

Their carefully tended mini brains formed optic cups as early as 30 days into development, with the structures clearly visible at 50 days. This is consistent with the timing of eye development in the human embryo, which means these organoids could be useful for studying the intricacies of this process.

There are other implications, too. The optic cups contained different retinal cell types, which organized into neural networks that responded to light, and even contained lens and corneal tissue. Finally, the structures displayed retinal connectivity to regions of the brain tissue.

"In the mammalian brain, nerve fibers of retinal ganglion cells reach out to connect with their brain targets, an aspect that has never before been shown in an in vitro system," Gopalakrishnan said.

And it's reproducible. Of the 314 brain organoids the team grew, 73 percent developed optic cups. The team hopes to develop strategies for keeping these structures viable on longer time-scales for performing more in-depth research with huge potential, the researchers said.

"Optic vesicle-containing brain organoids displaying highly specialized neuronal cell types can be developed, paving the way to generate personalized organoids and retinal pigment epithelial sheets for transplantation," they wrote in their paper.

"We believe that [these] are next-generation organoids helping to model retinopathies that emerge from early neurodevelopmental disorders."

The research has been published in Cell Stem Cell.

A version of this article was first published in August 2021.

Follow this link:
Scientists Grew 'Mini Brains' From Stem Cells. Then, The Brains Sort-of Developed Eyes. - ScienceAlert

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

NEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.

More here:
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache.

Continue reading here:
electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation.

Continue reading here:
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Nusano to Host December 19 Virtual KOL Event on Emerging Trends in Radiotherapeutics

VALENCIA, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will host a virtual KOL event on December 19, 2023 at 11:00 AM ET, led by Suji Jeong PhD (Founding Partner, The SJR Group), featuring Phil Nicklin (Senior Analyst, LifeSci Consulting) and Dr. Ashley Mishoe, PharmD (Vice President of Regulatory Affairs and Quality Assurance, PharmaLogic). They will discuss emerging trends in the radiotherapeutics landscape, a market that is projected to have a $30 billion potential in the next five years, a prospect that is capturing the attention of investors and companies alike. To register, click here.

Link:
Nusano to Host December 19 Virtual KOL Event on Emerging Trends in Radiotherapeutics

Bon Natural Life Limited Announces Major Breakthrough in Apple Polyphenol Technology, Set to Boost Fiscal 2024 Sales

XI’AN, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solution providers in the natural, health and personal care industries, today announced that the Company has achieved significant breakthrough in apple polyphenol extraction technology. This development is set to drive considerable growth in BON's apple polyphenol products in the upcoming fiscal year.

Read the rest here:
Bon Natural Life Limited Announces Major Breakthrough in Apple Polyphenol Technology, Set to Boost Fiscal 2024 Sales

Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three…

PALO ALTO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has signed an insurance coverage agreement for ELYXYB® with a national PBM, for their Medicare population potentially expanding coverage of ELYXYB®.

Read the rest here:
Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three...